Globeflex Capital L P Boosts Stock Holdings in Bioventus Inc. $BVS

Globeflex Capital L P increased its stake in Bioventus Inc. (NASDAQ:BVS) by 59.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 123,052 shares of the company’s stock after acquiring an additional 45,936 shares during the period. Globeflex Capital L P owned approximately 0.15% of Bioventus worth $1,123,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd grew its stake in Bioventus by 17,156.2% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock worth $41,000 after purchasing an additional 5,490 shares in the last quarter. Prelude Capital Management LLC acquired a new stake in Bioventus in the 3rd quarter valued at about $74,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Bioventus in the 3rd quarter valued at about $78,000. SG Americas Securities LLC purchased a new position in shares of Bioventus in the 4th quarter valued at about $80,000. Finally, Brooklyn Investment Group purchased a new position in shares of Bioventus in the 4th quarter valued at about $91,000. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Bioventus Trading Down 2.1%

NASDAQ:BVS opened at $11.63 on Thursday. The stock has a 50-day simple moving average of $9.97 and a 200-day simple moving average of $9.24. The stock has a market cap of $971.57 million, a P/E ratio of 28.37, a P/E/G ratio of 1.51 and a beta of 0.65. Bioventus Inc. has a 1 year low of $5.81 and a 1 year high of $12.53. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69.

Bioventus (NASDAQ:BVS) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.The business had revenue of $132.09 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, analysts anticipate that Bioventus Inc. will post 0.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Canaccord Genuity Group restated a “buy” rating and set a $15.00 target price on shares of Bioventus in a research note on Tuesday, June 16th. Barrington Research reiterated an “outperform” rating and issued a $14.00 price target on shares of Bioventus in a research note on Tuesday, June 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bioventus in a report on Tuesday, June 2nd. Finally, CJS Securities initiated coverage on shares of Bioventus in a research report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $14.75.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.